

September 07, 2026

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd. Exchange
Plaza, 5th floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: Business Responsibility and Sustainability Report (BRSR)

Please find enclosed the Business Responsibility and Sustainability Report of the Company for the Financial Year 2025-26.

The copy of the same is also available on the website of the Company viz., www.fischermv.com/ir

This is for your information and records.

Thanking You,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

BALAJI GANDLA

Digitally signed by BALAJI
GANDLA
Date: 2026.09.07 21:00:24 +05'30'

BALAJI GANDLA

COMPANY SECRETARY & COMPLIANCE OFFICER



Annexure IV

Business Responsibility and Sustainability Reporting

SECTION A: GENERAL DISCLOSURES

I. Details of the Listed Entity

1.	Corporate Identity Number (CIN) of the Listed Entity. -	L86900AP1993PLC118162
2.	Name of the Listed Entity -	FISCHER MEDICAL VENTURES LIMITED
3.	Year of Incorporation -	1993
4.	Registered Office Address -	No.480/2, Andhra Pradesh Medtech Zone Limited, Nadapura Village, Pedagantyada Mandal, Nadupuru, Visakhapatnam, Andhra Pradesh, India, 530031
5.	Corporate Address. -	Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai - 600 006, Tamil Nadu
6.	E-mail –	cs@fischermv.com
7.	Telephone -	+91 9080966548
8.	Website –	www.fischermv.com
9.	Financial Year for which reporting is being done -	2025 - 2026
10.	Name of the Stock Exchange(s) where shares are listed -	I. Bombay Stock Exchange II. National Stock Exchange of India
11.	Paid-up Capital -	Rs. 65,45,15,470
12.	Name and contact details of the person to be contacted for BRSR queries (Telephone, Email) -	Mr. Balaji Gandla Company Secretary & Compliance officer +91 9080966548 cs@fischermv.com
13.	Reporting Boundary – Standalone or Consolidated? -	Standalone
14.	Name of Assurance Provider -	NA
15.	Type of Assurance Obtained -	NA

II. Products / Services

16. Details of business activities (accounting for 90% of the turnover):

S.No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1	Manufacturing and Trading	Medical devices and software including radiology and preventive and other healthcare devices	100%

17. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):

S.No.	Product / Service	NIC Code	% of Total Turnover contributed
1	Medical devices and software including radiology and preventive Healthcare devices	86909	100%

III. Operations

18. Number of locations where plants and/or operations/offices of the entity are situated:

Location	No. of Plants	No. of Offices	Total
National	1	2	3
International	0	0	0

**19. Markets served by the entity:****a. Number of locations**

Locations	Number
National (No. of States)	9
International (No. of Countries)	7

b. What is the contribution of exports as a percentage of the total turnover of the entity?

0

c. A brief on types of customers:

Fischer Medical Ventures Limited (FMVL) operates on a B2B model, with its customers comprising diagnostic centers, hospitals, corporate healthcare providers, governments and public health institutions, as well as other companies in the healthcare ecosystem, including technology firms and MedTech companies. FMVL also delivers preventive healthcare solutions, enabling early detection and proactive screening through its cost-efficient, high- quality MRI systems that enhance diagnostic capabilities, strengthen healthcare delivery, promote preventive health, and support imaging needs across both private and government sectors in India and outside India.

IV. Employees**20. Details as at the end of Financial Year:****a. Employees and workers (including differently abled): -**

Sr. No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B/A)	No. (C)	% (C/A)
Employees (including differently abled)						
1.	Permanent (D)	16	12	75%	4	25%
2.	Other than permanent (E)	3	3	100%	0	0%
3.	Total employees (D + E)	19	15	78.95%	4	21.05%
Workers						
4.	Permanent (F)	0	0	0%	0	0%
5.	Other than Permanent (G)	0	0	0%	0	0%
6.	Total workers (F + G)	0	0	0%	0	0%

b. Differently abled Employees and workers:

S. No.	Particulars	Total (A)	No. (B)	% (B/A)	No. (C)	% (C/A)
DIFFERENTLY ABLED EMPLOYEES						
1	Permanent (D)	0	0	0%	0	0%
2	Other than Permanent (E)	0	0	0%	0	0%
3	Total Differently Abled Employees (D+E)	0	0	0%	0	0%
DIFFERENTLY ABLED WORKERS						
4	Permanent (F)	0	0	0%	0	0%
5	Other than Permanent (G)	0	0	0%	0	0%
6	Total Differently Abled Workers (F+G)	0	0	0%	0	0%

21. Participation/Inclusion/Representation of women:

	Total (A)	No. and percentages of females	
		No. of Females (B)	% (B/A)
Board of Directors	8	2	25.00%
Key Management Personnel	2	0	0.00%

22. Turnover rate for permanent employees and workers (Disclose trend for the past 3 years):

	FY 2025-26 (Current FY) *			FY 2024-25 (Previous FY)			FY 2023-24 (Prior to Previous FY)		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	19.05%	0.00%	14.29%	9.00%	0.00%	9.00%	0.00%	0.00%	0.00%
Permanent Workers	NA								

*The methodology of calculation for employee's turnover rate is changed, according to BRSR.

V. Holding, Subsidiary and Associate Companies (including joint ventures)

23. (a) Names of holding / subsidiary / associate companies / joint ventures:

S. No.	Name of Holding/Subsidiary/ Associate/Joint Ventures (A)	Indicate Whether Holding/Subsidiaries/ Associates/Joint Ventures	% of Shares held by listed entity	Does the entity indicated at column A, participate in Business Responsibilities Initiatives? (Yes/No)
1	FMV Holdings PTE Limited	Holding	50.69	No
2	Time Medical International Ventures (I) (P) Limited	Subsidiary	100.00	Yes
3	FlynnCare Health Innovations Private Limited	Subsidiary	100.00	Yes
4	Wondertech Medical Solutions Private Limited	Subsidiary	51.00	Yes
5	Nanyang Biologics (India) Private Limited	Subsidiary	51.00	Yes
6	Pellucidcare Health Innovations Pte Ltd (FKA FMV Healthcare PTE Limited)	Subsidiary	100.00	No
7	FMV International Ventures Pte Ltd	Subsidiary	100.00	No
8	FMV Global Innovation Pte Ltd	Subsidiary	100.00	No
9	Fischer Hospitality Sdn Bhd	Subsidiary	60.00	No
10	Time Medical Philippines Inc	Subsidiary	75.00	No
11	Blusim Tech Pte Limited	Associate	20.00	No
12	The Therapy Platform Pte Limited	Associate	20.00	No

VI. CSR Details

24. CSR Applicability (as per section 135 of Companies Act, 2013):

(i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) -

No

(ii) Turnover (in ₹): 1,739.18 Lakhs



(iii) **Net worth (in ₹):** 33,813.23 Lakhs

VII. Transparency and Disclosures Compliances

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines for Responsible Business Conduct:

Stakeholder Group	Grievance Redressal Mechanism in Place (Yes/No)	FY 2025-26 (Current FY)			FY 2024-25 (Previous FY)		
		Filed	Pending	Remarks	Filed	Pending	Remarks
Communities	Yes	0	0	NA	0	0	NA
Investors (other than shareholders)		0	0	NA	0	0	NA
Shareholders		2	0	NA			
Employees and Workers		2	0	No Pending Queries	0	0	NA
Customers		0	0	NA	0	0	NA
Value Chain Partners		0	0	NA	0	0	NA
Other		0	0	NA	0	0	NA

26. Overview of the entity's material responsible business conduct issues

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with the financial implications, as per the following format

Material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to the Company's business are set out below, together with the rationale for identifying each issue, the Company's approach to mitigating identified risks, and the associated financial implications. The material issues identified are consistent with those reported in the previous financial year.

Material Issue Identified	R/O	Rationale for Identifying the Risk / Opportunity	Approach to Risk Mitigation	Financial Implications
Product Quality and Patient Safety	R	MRI systems are classified as high-risk medical devices. Any product defect or performance failure could compromise patient safety, result in product recalls and lead to regulatory action.	The Company maintains its ISO 13485:2016 certification, strengthens its quality assurance and post-market surveillance systems, provides regular technical training to service personnel, and continuously monitors product performance to ensure quality, safety, and customer satisfaction.	Negative – Potential reputational damage, regulatory action, legal liabilities and compliance-related costs.
Responsible Supply Chain Management	O	A resilient and responsibly managed supply chain supports product quality, operational continuity and cost efficiency across the value chain.	NA	Positive – Improved product quality, operational efficiency and cost optimisation.

Material Issue Identified	R/O	Rationale for Identifying the Risk / Opportunity	Approach to Risk Mitigation	Financial Implications
Energy Use	O	Efficient energy management enhances operational efficiency, lowers energy costs and reduces the Company's environmental footprint. The adoption of helium-free MRI technology can further support resource efficiency by reducing dependence on helium, a finite resource, while supporting more sustainable MRI operations.	NA	Positive – Reduced operating costs and improved resource efficiency.
E-waste and Extended Producer Responsibility (EPR)	R	MRI systems and electronic components contain materials requiring environmentally responsible end-of-life management and regulatory compliance.	Collaborate with authorised e-waste recyclers, incorporate disposal and dismantling guidelines in user manuals, and strengthen EPR compliance mechanisms.	Negative – Potential regulatory penalties, compliance costs and restrictions on business operations.
Data Privacy and Cybersecurity	R	Any compromise of MRI-linked software or digital diagnostic platforms may result in unauthorised access to sensitive patient data and disruption of business operations.	Implement the ISO 27001 information security framework, conduct periodic vulnerability assessments and penetration testing, and strengthen employee cybersecurity awareness.	Negative – Potential financial losses, regulatory exposure and reputational impact.
Workforce Health, Safety and Retention	O	A safe, healthy and engaged workforce enhances productivity, strengthens employee retention and supports operational excellence.	NA	Positive – Lower recruitment and employee replacement costs, with improved workforce productivity.
Access to Healthcare / Affordability	O	Limited access to affordable diagnostic imaging in rural and Tier II/III markets presents an opportunity to expand access through cost-effective MRI solutions.	NA	Positive – Revenue growth through increased market penetration and improved healthcare accessibility.



SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Policy and Management Processes

1. Policy coverage across NGRBC Principles:

Disclosure Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
1a. Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
1b. Has the policy been approved by the Board? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
1c. Web Link of the Policies, if available	www.fischermv.com/ir								

2. Whether the entity has translated the policy into procedures. (Yes / No)

Disclosure Question	P1	P2	P3	P4	P5	P6	P7	P8	P9
Translated into procedures? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

3. Do the enlisted policies extend to your value chain partners? (Yes/No)

Disclosure Question	P1	P2	P3	P4	P5	P6	P7	P8	P9
Extends to value chain partners? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

P1: - Businesses should conduct and govern themselves with integrity, and in a manner that is ethical, transparent and accountable.

P2: - Businesses should provide goods and services in a manner that is sustainable and safe

P3: - Businesses should respect and promote the well-being of all employees, including those in their value chains

P4: - Businesses should respect the interests of and be responsive to all its stakeholders

P5: - Businesses should respect and promote human rights

P6: - Businesses should respect and make efforts to protect and restore the environment

P7: - Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

P8: - Businesses should promote inclusive growth and equitable development.

P9: - Businesses should engage with and provide value to their consumers in a responsible manner

4. Name of the national and international codes/certifications/labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.

The Company has got the following ISO Certification:

ISO 9001:2015 for Supply of Medical devices and Pharma Products the Company also have FSSAI License & Drug License Time Medical International Ventures (India) Private Limited (TMIV), the Wholly Owned Subsidiary of the Company has got the following ISO Certifications:

ISO13485:2016 for Quality Management System for Medical Devices ISO 13485:2016 for Design, Development, Manufacturing, Supply Installation and Servicing of MRI Scanning Machine and Suppliers of MRI accessories and spares.

TMIV maintains the required Factory Licenses, Pollution Control Certificates, Drug Licenses and other applicable statutory approvals and certifications for the manufacturing of MRI machines. The Company has also obtained the necessary CDSCO approval, demonstrating its commitment to regulatory compliance, product quality, safety and responsible manufacturing practices.

5. Specific commitments, goals and targets set by the entity with defined timelines, if any.

Fischer Medical Ventures Limited is committed to embedding ESG principles into its business strategy and operational practices. As the sustainability framework continues to evolve and mature, no formal time-bound ESG commitments, goals or quantitative targets have been established. Measurable sustainability objectives will continue to be evaluated in alignment with strategic priorities, evolving stakeholder expectations and the applicable regulatory landscape.

6. Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.

This report emphasises the efforts and steps taken by the Company to promote sustainability and addresses our specific areas of focus on Environmental, Social, and Governance (ESG) issues throughout the Financial Year. Moving ahead, we are dedicated to monitoring and disclosing our progress regarding these commitments in the future

Governance, Leadership and Oversight

7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements (listed entity has flexibility regarding the placement of this disclosure)

Dear Shareholders,

At Fischer Medical Ventures Limited (FMVL), our purpose extends beyond manufacturing advanced medical technologies—it is driven by the belief that quality healthcare should be accessible to all. This philosophy shapes every decision we make and underpins our commitment to creating sustainable value for patients, healthcare providers, employees, business partners and the communities we serve.

Our Business Responsibility and Sustainability journey reflects the manner in which we integrate environmental stewardship, social responsibility and sound governance into our business strategy. As we continue to strengthen our capabilities in indigenous MRI manufacturing, we remain focused on building a resilient organisation that creates long-term value while contributing to society.

Environmental Responsibility

As a manufacturer of precision medical technologies, we recognise our responsibility to minimise our environmental footprint. During the year, we continued to strengthen our resource efficiency initiatives and waste management practices while enhancing our approach towards responsible handling of e-waste and hazardous materials at our manufacturing facility within the Andhra Pradesh MedTech Zone. As our operations continue to expand, we remain committed to further strengthening our environmental management practices and embedding sustainability considerations across our manufacturing processes.

Social Commitment

Our people are the cornerstone of our success. We continued to invest in strengthening employee capabilities through regular technical and safety training across specialised disciplines, including magnetics, software integration and machine calibration. I am pleased to share that we maintained our record of zero workplace accidents during the year, reflecting our unwavering commitment to fostering a safe and healthy work environment.

Beyond our organisation, we remain committed to advancing access to affordable diagnostic imaging solutions. By supporting the development of indigenous MRI technologies, we seek to improve healthcare accessibility, particularly across underserved rural and Tier II and Tier III markets where access to quality diagnostic infrastructure continues to remain limited.

Governance and Ethics

Strong governance continues to serve as the foundation of our business. During the year, we further strengthened our data protection and cybersecurity framework in line with India's Digital Personal Data Protection requirements, recognising that trust in our digital healthcare solutions is fundamental to our long-term success.

We also reinforced our commitment to ethical business conduct by further embedding our Code of Conduct across the organisation, strengthening our whistleblower framework and promoting a culture founded on integrity, transparency and accountability. In parallel, we continued to extend our Supplier Code of Conduct across the value chain to encourage responsible sourcing, fair labour practices and environmental responsibility among our business partners.



Looking Ahead

India's healthcare ecosystem presents significant opportunities to improve diagnostic accessibility through innovation and indigenous manufacturing. While the industry continues to evolve amidst technological advancements and increasing regulatory expectations, we remain focused on delivering high-quality medical technologies while upholding the highest standards of safety, quality, governance and responsible business conduct.

The progress achieved during the year has further strengthened the foundation for sustainable growth. As we move forward, we remain committed to creating lasting value for all our stakeholders while contributing towards a more accessible, resilient and sustainable healthcare ecosystem.

On behalf of the Board, I extend my sincere gratitude to our shareholders, customers, employees, business partners and all other stakeholders for their continued trust and support. Together, we will continue to build a stronger organisation while advancing our shared vision of a healthier and more sustainable future.

Warm regards,

Ravindran Govindan

Chairman & Managing Director

8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy(ies).

Name/Designation: Ravindran Govindan, Chairman and Managing Director of the company is responsible for implementation and oversight of the business responsibility policies.

9. Does the entity have a specified Committee of the Board / Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.

No.

10. Details of Review of NGRBCs by the Company.

Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/Any other Committee									Frequency (Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action									Director									Periodically / Need based
Compliance with statutory requirements of relevance to the principles, and, rectification of any non-compliances									Director									Periodically / Need based

11. Has the entity carried out independent assessment/evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency:

Disclosure Question	P1	P2	P3	P4	P5	P6	P7	P8	P9
Independent assessment conducted? (Yes/No) If Yes – Name of Agency	The working of the policy is also ensured by various department heads/ directors/board committees/board members, wherever applicable.								

12. If answer to Question 1 above is 'No' (i.e. not all Principles are covered by a policy), reasons to be stated:

Disclosure Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the principles material to its business (Yes/No)					NA				
The entity is not at a stage where it is in a position to formulate and implement policies on specified principles (Yes/No)					NA				
The entity does not have the financial or/ human and technical resources available for the task (Yes/No)					NA				
It is planned to be done in the next financial year (Yes/No)					NA				
Any other reason (please specify)					NA				

SECTION C: PRINCIPLE-WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as "Essential" and "Leadership". While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.

PRINCIPLE 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable

Essential Indicators

- Percentage coverage by training and awareness programmed on any of the Principles during the financial year:

Segment	Total No. of Training & Awareness Programmes Held	Topics / Principles Covered & Impact	% of Persons in Category Covered
Board of Directors	1	Board Diversity, Familiarization Program of Roles & Responsibilities of Independent Directors	100%
Key Managerial Personnel	1	Corporate Governance, Regulatory Compliances	100%
Employees other than BoD and KMPs	2	Code of Conduct & POSH Awareness Sessions	100%
Workers	NA	NA	NA

- Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):**

Monetary:

NGRBC Principles	Name of the regulatory/ enforcement agencies/ judicial institutions	Monetary Amount (In INR)	Brief of the Case	Has an appeal been preferred? (Yes/ No)
Penalty/ Fine		Nil		
Settlement		Nil		

NGRBC Principles	Name of the regulatory/ enforcement agencies/ judicial institutions	Monetary Amount (In INR)	Brief of the Case	Has an appeal been preferred? (Yes/ No)
	Compounding fee	Nil		

Non-Monetary:

Type	NGRBC Principle	Name of Agency	Brief of Case
Imprisonment		Nil	
Punishment		Nil	

3. Of the instances disclosed in Question 2 above, details of the Appeal/Revision preferred in cases where monetary or non-monetary action has been appealed:

Name of Authority / Case Details	Corrective Action Taken / Underway
NA	NA

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy:

Yes, the Company has a comprehensive Anti-Corruption and Anti-Bribery Policy, available as part of the Code of Conduct, underscoring our commitment to ethical, transparent, and fair business practices. For more details, please visit our policy section on our website www.fischermv.com/ir

5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:

Category	FY 2025-26 (Current FY)	FY 2024-25 (Previous FY)
Directors	0	0
KMPs	0	0
Employees	0	0
Workers	0	0

6. Details of complaints with regard to conflict of interest:

Complaint Type	FY 2025-26 (Current FY)		FY 2024-25 (Previous FY)	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	0	NA	0	NA
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	0	NA	0	NA

7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators / law enforcement agencies / judicial institutions, on cases of corruption and conflicts of interest:

Not Applicable

8. Number of days of accounts payables ((Accounts payable × 365) / Cost of goods/services procured):

Parameter	FY 2025-26 (Current FY)	FY 2024-25 (Previous FY)
Number of days of accounts payables ((Accounts payable × 365) / Cost of goods/ services procured)	114.65	82

9. Openness of business

Provide details of concentration of purchases and sales with trading houses, dealers, related parties along with loans, advances and investments with related parties, in the following format:

Parameter	Metrics	FY 2025-26 (Current FY)	FY 2024-25 (Previous FY)
Concentration of Purchases			
a.	Purchases from trading houses as % of total purchases	0	0
b.	Number of trading houses where purchases are made from	0	0
c.	Purchases from top 10 trading houses as % of total purchases from trading houses	0	0
Concentration of Sales			
a.	Sales to dealers/distributors as % of total sales	0	0
b.	Number of dealers/distributors to whom sales are made	0	0
c.	Sales to top 10 dealers/distributors as % of total sales to dealers/ distributors	0	0
Share of RPTs (Related Party Transactions)			
a.	Purchases with related parties / Total Purchases	0	0
b.	Sales to related parties / Total Sales	0	0
c.	Loans & advances given to related parties / Total loans & advances	0	15.06%
d.	Investments in related parties / Total Investments made	9.86%	86.21%

Leadership Indicators

1. Awareness programmes conducted for value chain partners on any of the Principles during the financial year:

Total No. of Awareness Programmes Held	Topics / Principles Covered under the Training	% of Value Chain Partners Covered (by value of business done with such partners) under the awareness programmes
Nil	NA	NA

2. Does the entity have processes in place to avoid/manage conflict of interests involving members of the Board? (Yes/ No). If Yes, provide details:

Yes, the Company has processes in place to manage potential conflicts of interest involving Board members. All Board members and Key Managerial Personnel (KMP) submit an annual declaration of their interests in other entities. Any potential conflicts are disclosed, and necessary actions are taken as per the Company's Code of Conduct and Related Party Transactions Policy. Transactions involving such entities require prior approval from the Audit Committee or the Board. Additionally, Directors abstain from voting or participating in discussions where a conflict of interest may exist.

**PRINCIPLE 2: Businesses should provide goods and services in a manner that is sustainable and safe****Essential Indicators**

1. **Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.**

	Current FY	Previous FY	Details of Environmental/Social Improvements
R&D	0	0	No expenses incurred
Capex	0	0	

2. **Does the entity have procedures in place for sustainable sourcing? (Yes/No). If yes, what percentage of inputs were sourced sustainably?**

- a. **Procedures in place for sustainable sourcing:**

Yes

- b. **If yes, percentage of inputs sourced sustainably:**

The entity has procedures in place for sustainable sourcing, with approximately 40% of its inputs sourced sustainably.

3. **Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.**

Our company is dedicated to becoming a leader in sustainable fashion, embedding sustainability into every business decision across the ecosystem and promoting responsible disposal to create value for all stakeholders.

Plastics (including packaging)	Plastics (including Plastic parts are marked with recyclability symbols for easy identification during recycling packaging processes.
E-waste	The batteries used in our products are marked with recycling symbols. At the end of their life cycle, these batteries are sent to recyclers through our dealers and channel partners.
Hazardous waste	We have limited the use of 'hazardous chemicals' in the components used in our products. We have established an internal standard that aligns with various national and international laws concerning hazardous substances.
Other waste	Towards facilitating environmentally friendly disposal of products at end-of-life, our products are designed with increased recyclability and recoverability rates to promote recycling.

4. **Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities? (Yes / No). If yes, whether the waste collection plan is in line with the EPR plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.**

No

Leadership Indicators

1. **Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? If yes, provide details in the following format?**

NIC Code	Name of Product/ Service	% of Total Turnover Contributed	Boundary for LCA	Conducted by Independent External Agency (Yes/ No)	Results in Public Domain (Yes/ No) & Web-link
No LCA has been conducted for current financial year FY26					

2. Significant social or environmental concerns/risks arising from production or disposal of products/services as identified in LCA or other means:

Name of Product/Service	Description of Risk / Concern	Action Taken
	NA	

3. Percentage of recycled or reused input material to total material (by value) used in production/providing services:

Indicate Input Material	FY 2025-26 (Current FY)	FY 2024-25 (Previous FY)
	Recycled or re-used input material to total material	
	NA	

4. Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed:

	FY 2025-26 (Current FY)			FY 2024-25 (Previous FY)		
	Re-Used	Recycled	Safely Disposed	Re-Used	Recycled	Safely Disposed
Plastics (including packaging)	NA	NA	NA	NA	NA	NA
E-waste						
Hazardous waste						
Other waste						

5. Reclaimed products and their packaging materials (as percentage of products sold) for each product category:

Indicate Product Category	Reclaimed Products and Packaging as % of Total Products Sold in Category
Nil	NA

PRINCIPLE 3: Businesses should respect and promote the well-being of all employees, including those in their value chains

Essential Indicators

1. Details of measures for well-being of employees and workers:

a. Well-being of employees:

Category	Total (A)	% of employees covered by									
		Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day care facilities	
		No. (B)	% (B/A)	No. (C)	% (C/A)	No. (D)	% (D/A)	No. (E)	% (E/A)	No. (F)	% (F/A)
Permanent employees											
Male	12	12	100%	12	100%	NA	NA	12	100	0	0
Female	4	4	100%	4	100%	4	100%	NA	NA	0	0
Total	16	16	100%	16	100%	4	25%	12	75%	0	0
Other than permanent employees											
Male	3	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0
Total	3	0	0	0	0	0	0	0	0	0	0

**b. Well-being of workers:**

% of workers covered by											
Category	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day care facilities	
		No. (B)	% (B/A)	No. (C)	% (C/A)	No. (D)	% (D/A)	No. (E)	% (E/A)	No. (F)	% (F/A)
Permanent workers											
Male											
Female											
Total											
Other than permanent workers											
Male											
Female											
Total											

Not Applicable. No workers

Not Applicable. No workers

c. Spending on measures towards well-being of employees and workers:

Parameter	FY 2025-26 (Current FY)	FY 2024-25 (Previous FY)
Cost incurred on wellbeing measures as a % of total revenue of the company	11.59%	0.48%

2. Details of retirement benefits, for Current FY and Previous Financial Year:

Benefits	FY 2025-26			FY 2024-25		
	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/NA)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/NA)
PF	100%	NA	Y	100%	0	Y
Gratuity	100%	NA	Y	100%	0	Y
ESI	0	NA	0	4%	0	Y
Others – please specify	0	NA	0	0%	0	NA

3. Accessibility of workplaces – Are the premises / offices accessible to differently abled employees and workers, as per the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.

Yes

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy:

Yes, the relevant policies are incorporated into the Company's Code of Conduct (CoC) and are available to employees through the Company's Intranet. Further information is available on the Company's website: www.fischermv.com/ir

5. Return to work and Retention rates of permanent employees and workers that no employees took parental leave

Gender	Permanent Employees – Return to Work Rate	Permanent Employees – Retention Rate	Permanent Workers – Return to Work Rate	Permanent Workers – Retention Rate
Male	0	0	0	0
Female	0	0	0	0
Total	0	0	0	0

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and workers?

Category of employees and workers covered	Yes/No	Grievance procedure mechanism in brief
Permanent Workers	Yes	Our Company's POSH committee comprises members from diverse groups. Whistle-blower Policies and a Code of Conduct (CoC) are available for all categories of permanent employees and workers. Dedicated channels for raising grievances have been established and communicated to all stakeholders. Employees can contact the committee via phone or e-mail.
Other than Permanent Workers	Yes	
Permanent Employees	Yes	
Other than Permanent Employees	Yes	

7. Membership of employees and workers in association(s) or Unions recognised by the listed entity:*

Category	FY 2025-26			FY 2024-25		
	Total employees / workers in respective category (A)	No. of employees / workers in respective category, who are part of association(s) or Union (B)	% (B / A)	Total employees / workers in respective category (C)	No. of employees / workers in respective category, who are part of association(s) or Union (D)	% (D / C)
Total Permanent Employees	16	0	0%	40	0	0
Male	12	0	0%	31	0	0
Female	4	0	0%	9	0	0
Total Permanent Workers	0	0	0%	0	0	0
Male	3	0	0%	0	0	0
Female	0	0	0%	0	0	0

*This FY the numbers are based on standalone and the previous year was in consolidated basis

8. Details of training given to employees and workers:

Category	FY 2025-26*					FY 2024-25				
	Total (A)	Health and safety measures		Skill upgradation		Total (D)	Health and safety measures		Skill upgradation	
		No. (B)	% (B/A)	No. (C)	% (C/A)		No. (E)	% (E/ D)	No. (F)	% (F/D)
Employees										
Male	12	12	100%	12	100%	31	31	100%	27	87%
Female	4	4	100%	4	100%	9	9	100%	7	77%
Total	16	16	100%	16	100%	40	40	100%	34	85%
Workers										
Male										
Female										
Total										

Not Applicable. No workers

*This FY the numbers are based on standalone and the previous year was in consolidated basis

**9. Details of performance and career development reviews of employees and workers:**

Category	FY 2025-26			FY 2024-25		
	Total (A)	No. (B)	% (B/A)	Total (C)	No. (D)	% (D/C)
Employees						
Male	12	7	58.33%	31	25	81%
Female	4	3	75%	9	6	67%
Total	16	10	62.50%	40	31	77%
Workers						
Male						
Female						
Total						

Not Applicable. No workers**10. Health and safety management system:****a. Whether an occupational health and safety management system has been implemented? (Yes/No). If yes, the coverage:**

Yes, FMVL has implemented an Occupational Health and Safety management system, primarily covering its employees at offices and manufacturing facilities. The system ensures a safe and healthy work environment through regular medical check-ups, awareness sessions, and compliance with applicable safety standards, even though the nature of operations does not involve significant occupational hazards.

b. Processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity:

Fischer Medical Ventures Limited has established a comprehensive framework for the identification of work-related hazards and risk assessment, applicable to both routine and non-routine activities. The processes are structured to ensure proactive detection, evaluation, and mitigation of potential risks, and include the following:

- Periodic Safety Audits and Walk-through Inspections — conducted at regular intervals to systematically identify hazards and verify compliance with safety protocols and regulatory requirements.
- Occupational Health Surveillance and Safety Surveys — integrated into ongoing operations to track employee health trends and flag emerging workplace risks.
- Environmental, Health and Safety (EHS) Committee Meetings — held regularly with senior management, employees and contractors to review safety performance and address reported concerns.
- Annual External Safety Audits — conducted by independent experts to benchmark practices against industry standards.
- Hazard Identification and Risk Assessment (HIRA) Framework — applied across all operations to evaluate the probability and severity of identified risks and implement targeted controls.
- ISO 45001:2018 Integration — The Company's occupational health and safety management system is aligned with ISO 45001:2018 standards, ensuring systematic implementation of safety practices across routine tasks and non-routine or high-risk operations.

Through these structured processes, Fischer Medical Ventures Limited ensures a safe and health-conscious work environment while fostering a culture of continuous improvement in occupational risk management.

c. Whether processes exist for workers to report work related hazards and to remove themselves from such risks: (Y/N)

NA

d. Do employees/workers of the entity have access to non-occupational medical and healthcare services? (Yes/No)

Yes. The Company provides employees access to non-occupational medical and healthcare services through a comprehensive medical insurance plan and tie-ups with external healthcare providers and hospitals. Basic first aid facilities are available on-site for minor health concerns.

11. Details of safety related incidents:

Safety Incident/No. for the FY 2025-26 and 2024-25

Safety Incident/Number	Category	FY2025-26	FY2024-25
Lost time Injury frequency rate (LTIFR) (per one million-person hours worked)	Employee	0	0
	Worker	NA	
Total recordable work-related injuries	Employee	0	0
	Worker	NA	
No. of fatalities	Employee	0	0
	Worker	NA	
High consequence work-related injury or ill-health (excluding fatalities)	Employee	0	0
	Worker	NA	

12. Describe the measures taken by the entity to ensure a safe and healthy workplace.

At Fischer Medical Ventures Limited, ensuring a safe and healthy workplace is a core organisational priority, embedded within both our operational practices and our Code of Conduct. The Company adopts a proactive, systematic approach to occupational health and safety through the following key measures:

- Regular Safety Audits and Risk Assessments — comprehensive audits and routine risk assessments to identify potential hazards, enabling prompt corrective and preventive action.
- Ongoing Safety Training and Awareness — safety induction sessions and periodic awareness programmes to equip employees with the knowledge needed for safe operations.
- Occupational Health Monitoring — regular health check-ups, wellness initiatives and periodic medical camps to monitor and support employee well-being.
- On-site Medical Support — first-aid facilities and access to qualified medical professionals for timely assistance.
- Clean and Hygienic Facilities — routine sanitation of restrooms, availability of safe drinking water, and overall cleanliness of work areas.
- A Safe, Secure and Substance-free Workplace — in line with the Code of Conduct, weapons are prohibited on Company premises and the use of alcohol and drugs at work is strictly restricted, protecting employees from safety risks arising from impaired conduct.
- A Harassment-free Environment — a dedicated Internal Complaints Committee under the POSH Policy, together with the Code of Conduct's guiding principles of commitment, care, transparency and fairness, safeguards employees' psychological safety alongside their physical safety.
- Employee Participation in Safety Governance — safety committees and structured feedback mechanisms, together with the Company's confidential whistleblower channel, allow employees to raise safety concerns and contribute to continuous improvement without fear of retaliation.
- Statutory Compliance — adherence to the Factories Act, 1948, the Employees' Compensation Act, 1923, and the Occupational Safety, Health and Working Conditions Code, 2020, among other applicable health, safety and environmental laws.

These comprehensive measures collectively foster a culture of safety, mitigate occupational hazards, and uphold the physical and mental well-being of all employees across our operations.

13. Number of complaints on the following made by employees and workers:

No. of complaints on the following made by employees and workers	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working conditions	0	0	NA	0	0	NA
Health & safety	0	0	NA	0	0	NA

**14. Assessments for the year:**

Parameter	% of Plants and Offices Assessed (by entity or statutory authorities or third parties)
Health and safety practices	100%
Working Conditions	100%

15. Provide details of any corrective action taken or underway to address safety-related incidents and significant risks/ concerns arising from assessments of health & safety practices and working conditions.

NA

Leadership Indicators**1. Does the entity extend any life insurance or any compensatory package in the event of death of****(A) Employees (Y/N) – Yes,**

The Company provides life insurance coverage to employees as per statutory requirements under the Provident Fund-linked insurance scheme. In addition, Directors and Key Managerial Personnel (KMPs) are covered under Directors' and Officers' (D&O) Liability Insurance.

(B) Workers (Y/N) - 0**2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.**

Payment of statutory dues by all value chain partners is included as a contractual obligation.

3. Provide the number of employees / workers having suffered high consequence work-related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment.

Category	Total No. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2025-26	FY 2024-25	FY 2025-26	FY 2024-25
Employees	NA	NA	NA	NA
Workers	NA	NA	NA	NA

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/No)

No, The Company does not provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination.

5. Details on assessment of value chain partners:

Parameter	% of Plants and Offices Assessed
Health and safety practices	Nil
Working Conditions	Nil

6. Provide details of any corrective actions taken or underway to address significant risks/concerns arising from assessments of health and safety practices and working conditions of value chain partner.

NA

PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders

Essential Indicators

1. Describe the processes for identifying key stakeholder groups of the entity.

Fischer Medical Ventures Limited employs a structured stakeholder identification and engagement framework to recognize and prioritize key stakeholder groups. This process is informed by internal assessments, stakeholder mapping exercises, ongoing feedback mechanisms, and regular interactions across various levels of the organization.

Stakeholders are identified based on their level of influence on the Company's operations, as well as their interest in and potential impact from its activities. The primary stakeholder groups include employees, customers, investors, suppliers, regulatory authorities, and the communities in which the Company operates.

By maintaining active and transparent engagement with these stakeholders, Fischer Medical Ventures Limited ensures that their expectations, concerns, and priorities are systematically understood and appropriately integrated into its business strategy, risk management, and sustainability initiatives.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Stakeholder group	Whether identified as vulnerable & marginalised group (Yes/No)	Channels of communication (E-mail, SMS, newspaper, pamphlets, advertisement, community meetings, notice board, website, Other)	Frequency of engagement (Annually/ Half yearly/ Quarterly / others-please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Customers	No	E-mail, SMS, Newspapers and Advertisements, calls	As required	Frequent customer interaction, customer satisfaction surveys and other market surveys. Key Concerns: Product/service quality, timely delivery, and fair pricing of MRI machines
Dealers	No	E-mail, meetings	As required	Scope includes dealer management system, dealer meets, cluster meets, training on new products and our policies, facility visits and periodic communication. Key Concerns: Product quality, product handling, technological improvements, diverse customer requirements, and trained workforce.
Employees	No	E-mail, meetings	Regularly as required	Performance appraisal, employee engagement survey, grievance handling process, and training workshops. Key Concerns: Career planning, communication on employee related policies.
Community	Yes	Community Meetings	As required	Key Concerns: Community health and hygiene, infrastructure, livelihood, and education.NA

Stakeholder group	Whether identified as vulnerable & marginalised group (Yes/ No)	Channels of communication (E-mail, SMS, newspaper, pamphlets, advertisement, community meetings, notice board, website, Other)	Frequency of engagement (Annually/ Half yearly/ Quarterly / others-please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Polymakers	No	E-mail, Website	As required	Policy advocacy participation, industry associations. Key Concerns: No specific concerns
Regulatory bodies	No	E-mail, meetings.	As required	Submission of reports, inspection visits, need-based meetings on directives. Key Concerns: Regulatory compliance and transparency in disclosure
Shareholders/ investors	Yes	E-mail, Website, meetings	Annually, As required	Investor forums, corporate communication, annual general meetings, and annual reports. Key Concerns: Our strategy and performance, future plans, and returns to shareholders
Vendors, transporters and suppliers/ service providers	No	E-mails, policy statements, meetings, calls	As required	Supplier meets, supplier visits, supplier surveys, and supplier development group initiatives. Key Concerns: Communication within the supply chain regarding long-term plans financial transactions and updates on rejections Scheduling and fluctuating order volumes Early involvement of suppliers in new product development Performance management and rewards/ recognition systems

Leadership Indicators

- 1. Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.**

The Company has established appropriate channels for engaging with its stakeholders on matters relating to economic, environmental, and social topics. Inputs and feedback received from stakeholders through various engagement mechanisms are reviewed by the management. Matters that are considered significant or material are placed before the Board or the relevant Board Committees, as appropriate, to facilitate informed decision-making and oversight.

- 2. Whether stakeholder consultation is used to support the identification and management of environmental and social topics (Yes / No). If so, provide details of instances as to how inputs received from stakeholders were incorporated into policies and activities of the entity.**

Yes, Fischer Medical Ventures Limited actively engages in stakeholder consultations to support the identification and effective management of key environmental and social (E&S) topics. During FY 2024–25, the Company conducted a structured materiality assessment involving comprehensive surveys and targeted discussions with a diverse group of stakeholders, including employees, suppliers, customers, and strategic partners.

The insights gathered through this process were thoroughly reviewed by the senior management team and played a pivotal role in shaping the Company's E&S priorities. These inputs were directly integrated into relevant policies and operational strategies—particularly in the areas of occupational health and safety, employee well-being programs, environmental compliance, and resource efficiency.

By incorporating stakeholder perspectives into its decision-making framework, the Company ensures that its sustainability initiatives remain responsive, relevant, and aligned with broader stakeholder expectations and responsible business conduct.

3. Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/marginalized stakeholder groups.

Fischer Medical Ventures Limited remains steadfast in its commitment to promoting an inclusive, respectful, and equitable work environment. The Company actively engages with vulnerable and marginalized stakeholder groups, including contract workers, support staff, and individuals from economically disadvantaged backgrounds— through structured on-ground interactions and established internal feedback mechanisms.

In alignment with this commitment, the Company undertook the following initiatives during FY 2025–26:

Health and Safety Awareness: Organized dedicated awareness sessions focusing on personal hygiene, occupational health, and workplace safety to build awareness and promote well-being among all workers, especially those in vulnerable roles.

Equitable Access to Medical Services: Ensured that all categories of employees, regardless of employment status, had access to periodic medical check-ups and on-site first-aid support.

Grievance Redressal Mechanism: Strengthened the grievance redressal system to ensure that concerns raised by marginalized groups are promptly heard, documented, and addressed with sensitivity and fairness.

Inclusive Training and Onboarding: Provided tailored onboarding sessions and basic skill development support to workers with limited exposure to structured work environments, enabling smoother integration and enhancing their confidence.

These initiatives reflect the Company's broader objective of fostering dignity, inclusion, and equal opportunity for all members of its workforce, thereby contributing to a more just and sustainable workplace.

PRINCIPLE 5: Businesses should respect and promote human rights

Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:*

Category	FY 2025-26			FY 2024-25		
	Total (A)	No. of employees/workers covered (B)	% (B/A)	Total (C)	No. of employees/workers covered (D)	% (D/C)
Employees						
Permanent	16	16	100%	40	40	100%
Other than permanent	3	3	100%	9	8	89%
Total Employees	19	19	100%	49	48	98%
Workers						
Permanent						
Other than permanent						
Total Employees						

*This FY the numbers are based on standalone and the previous year was in consolidated basis

2. Details of minimum wages paid to employees and workers:*

Category	FY2025-26					FY2024-25				
	Total (A)	Equal to minimum wage		More than minimum wage		Total (D)	Equal to minimum wage		More than minimum wage	
		No. (B)	% (B/A)	No. (C)	% (C/A)		No. (E)	% (E/D)	No. (F)	% (F/D)
Employees-Permanent										
Male	4	0	0%	4	100%	31	0	0%	31	100%
Female	12	0	0%	12	100%	9	0	0%	9	100%
Total	16	0	0%	16	100%	40	0	0%	40	100%
Employees- Other than Permanent										
Male	3	0	0	3	100%	9	0	0	9	100%
Female	0	0	0	0	100%	0	0	0	0	0%
Total	3	0	0	3	100%	9	0	0	9	100%
Workers-Permanent										
Male	Not Applicable. No workers									
Female										
Total										
Workers- Other than Permanent										
Male	Not Applicable. No workers									
Female										
Total										

*This FY the numbers are based on standalone and the previous year was in consolidated basis

3. Details of remuneration / salary / wages:

a. Median remuneration / wages:

Category	No.	Male Median remuneration /salary/ wages of respective category (₹ in Lakh)	No.	Female Median remuneration/ salary/wages of respective category (₹ in Lakh)
Board of Directors (BoD) Executive	1	0	1	0
Board of Directors (BoD) Non-Executive	5	0	1	0
Key Managerial Personnel (KMP) (other than Board Members)	2	19.93 Lakhs	0	0
Employees other than BoD and KMP	10	15.7 Lakhs	4	5.45 Lakhs
Workers	0	0	0	0

b. Gross wages paid to females as % of total wages paid by the entity:

Parameter	FY 2025-26 (Current FY)	FY 2024-25 (Previous FY)
Gross wages paid to females as % of total wages	10.14%	18%

4. Do you have a focal point (Individual / Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes. We have several groups at the plant level dedicated to addressing employees’ health and safety concerns.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

FMVL believes in the dignity and rights of every individual and is committed to fostering a workplace built on fairness, respect, and inclusivity. We comply with all applicable human rights laws and ensure equal opportunity without discrimination based on gender, age, religion, ethnicity, or other protected status. To address grievances, employees may approach management through open communication channels without fear of retaliation. In addition, an Internal Complaints Committee (ICC) has been established under the POSH Act to address matters of sexual harassment, ensuring a safe and supportive work environment for all employees.

6. Number of complaints on the following made by employees and workers:

Nature of complaints	FY 2025-26		FY 2024-25	
	Filed during the year	Pending resolution at the end of year	Filed during the year	Pending resolution at the end of year
Sexual harassment	0	NA	0	NA
Discrimination at workplace	0	NA	0	NA
Child labour	0	NA	0	NA
Forced labour/involuntary labour	0	NA	0	NA
Wages	0	NA	0	NA
Other Human Rights related issues	0	NA	0	NA

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY 2025-26 (Current FY)	FY 2024-25 (Previous FY)
Total Complaints reported under POSH Act, 2013	0	0
Complaints on POSH as % of female employees/workers	0.00%	0.00%
Complaints on POSH upheld	NA	NA

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

The Company is committed to ensuring the safety, dignity, and rights of all employees and has established robust mechanisms to protect complainants in cases of discrimination and harassment. Strict confidentiality is maintained throughout the grievance resolution process, and any attempt to intimidate, retaliate against, or victimize the complainant is treated as a serious violation of the Company's Code of Conduct and is subject to disciplinary action.

The following procedures are adhered to:

- All complaints are addressed in a timely, sensitive, and impartial manner.
- Upon the request of the aggrieved employee, the matter may be resolved through mutual conciliation prior to the initiation of a formal inquiry. It is explicitly ensured that no monetary settlement shall form the basis for such conciliation.
- If a reconciliation is successfully reached, the Internal Committee prepares a formal written agreement reflecting the terms of the settlement. This agreement is signed by both parties and witnessed by the Committee and subsequently submitted to the management for record and implementation.
- The Committee ensures that copies of the settlement agreement—marked as unclassified, restricted, protected, or confidential as appropriate—are shared with both the complainant and the respondent.
- Once a settlement through conciliation is achieved, no further inquiry into the complaint shall be conducted.

These measures reflect the Company's unwavering commitment to fostering a safe, inclusive, and respectful work environment where employees feel empowered to raise concerns without fear of retaliation.

**9. Do human rights requirements form part of your business agreements and contracts? (Yes/No)**

Yes. Business agreements and contracts contain a standard provision of compliance with all applicable laws, conventions, and policies, among others, which encompasses the human rights requirements.

10. Assessments for the year:

	% of plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100%
Forced/involuntary labour	100%
Sexual harassment	100%
Discrimination at workplace	100%
Wages	100%
Others (please specify)	0%

11. Provide details of any corrective actions taken or underway to address significant risks/concerns arising from the assessments at Question 10 above.

NA

Leadership Indicators**1. Details of a business process being modified/introduced as a result of addressing human rights grievances/complaints.**

The Company has introduced several policies aimed at enhancing employee welfare and streamlining internal business processes. These initiatives are aligned with our Employee Code of Conduct and are designed to proactively mitigate potential grievances.

Key policies introduced include the Dress Code Policy, Flexible Working Hours Policy, the Prevention of Sexual Harassment (POSH) Policy, and the Whistleblower Policy. These policies collectively promote a fair, safe, and equitable work environment.

Additionally, the Company has strengthened its grievance redressal mechanism by enabling employees to express their concerns through both formal and informal channels. This multi-tiered approach ensures that all employees have access to a safe and confidential platform to voice their concerns, thereby reinforcing transparency, trust, and accountability within the organization.

2. Details of the scope and coverage of any Human rights due-diligence conducted.

Nil

3. Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Yes

4. Details on assessment of value chain partners:

	% of value chain partners (by value of business done with such partners) that were assessed
Sexual Harassment	0.00%
Discrimination at workplace	0.00%
Child Labour	0.00%
Forced Labour/Involuntary Labour	0.00%
Wages	0.00%
Others (please specify)	0.00%

5. Provide details of any corrective actions taken or underway to address significant risks/concerns arising from assessments at Question 4 above.

NA

PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment

Essential Indicators

1. Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:*

Parameter	Units	FY 2025-26	FY 2024-25
From renewable sources	GJ	0	0
Total electricity consumption (A)	GJ	0	0
Total fuel consumption (B)	GJ	0	0
Energy consumption through other sources (C)	GJ	0	0
Total energy consumption from renewable sources (A+B+C)	GJ	0	0
From non-renewable sources	GJ		
Total electricity consumption (D)	GJ	193.76	2,159.38
Total fuel consumption (E)	GJ	0	1.51
Energy consumption through other sources (F)	GJ	0	0
Total energy consumed from non-renewable sources (D+E+F)	GJ	193.76	0
Total energy consumed (A+B+C+D+E+F)	GJ	193.76	2,160.89
Energy intensity per ₹ of turnover (Total energy consumption (GJ)/ turnover in million ₹)	GJ/ Rs Crore	1.11	1,952.30
Energy intensity per rupee of turnover adjusted for purchasing power parity (PPP) (Total energy consumption/revenue from operations adjusted for PPP)	GJ/ Rs Crore (PPP Adjusted)	22.38	40,334.50
Energy intensity in terms of physical output			43.22
Note: Indicate if any independent assessment/evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency		No	No

*This FY the numbers are based on standalone and the previous year was in consolidated basis

2. Does the entity have any sites/facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any:

NA

3. Details related to water withdrawal and consumption, in the following format:

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

Water withdrawal by source	FY 2025-26	FY 2024-25
Water withdrawal by source (in kiloliters)		
Surface water (A)	0	0
Ground water (B)	0	44.53
Third party water (C)	48.94	18.1
Seawater/desalinated water (D)	0	0
Others (E)	0	0
Total volume of water withdrawal (A+B+C+D+E)	48.94	62.63
Total volume of water consumption	48.94	62.63
Water intensity per ₹ of turnover (Total water consumption (kl)/ turnover in million ₹)	0.28	56.58



Water withdrawal by source	FY 2025-26	FY 2024-25
Water intensity per ₹ of turnover adjusted for PPP (Total water consumption / revenue from operations adjusted for PPP)	5.65	1168.98
Water intensity in terms of physical output		1.25
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency	No	No

4. Provide the following details related to water discharged:

Water discharge by destination and level of treatment	FY 2025-26	FY 2024-25
Water discharge by destination and level of treatment (in kiloliters)		
Surface water (A)	0	0
No treatment		
With treatment-please specify level of treatment		
Ground water (B)	0	0
No treatment		
With treatment-please specify level of treatment		
Seawater (C)	0	0
No treatment		
With treatment-please specify level of treatment		
Third party water(D)	0	0
No treatment		
With treatment-please specify level of treatment		
Others (E)	0	0
No treatment		
With treatment-please specify level of treatment		
Total water discharged	0	0
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency	No	No

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

No

6. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:

Note: Indicate if any independent assessment has been carried out by an external agency? (Y/N) If yes, name the agency.

(Unit in tonne/Annum)

Parameter	FY 2025-26	FY 2024-25
NOx	NA	NA
SOx	NA	NA
Particulate matter (PM)	NA	NA
Persistent organic pollutants (POP)	NA	NA
Volatile organic compounds (VOC)	NA	NA
Hazardous air pollutants (HAP)	NA	NA
Others- please specify (CO)	NA	NA
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, me of the external agency	No	No

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:

Note: Indicate if any independent assessment has been carried out by an external agency? (Y/N) If yes, name the agency.

Parameter	Please specify unit	FY 2025-26*	FY 2024-25
Scope 1 emissions			
Total Scope 1 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tonnes of CO ₂ equivalent	0.00	0.1025
Scope 2 emissions			
Total Scope 2 emissions (Break-up of the GHG into CO ₂ , CH ₄ , N ₂ O, HFCs, PFCs, SF ₆ , NF ₃ , if available)	Metric tonnes of CO ₂ equivalent	38.21	436.074
Total scope 1 and scope 2 emissions intensity per ₹ of turnover (Total scope 1 and scope 2 GHG emissions/ turnover in million ₹)	Metric tonnes of CO ₂ equivalent/ Rs crore of Revenue	0.22	394.05
Total Scope 1 and Scope 2 emission intensity per ₹ of turnover adjusted for PPP (Total Scope 1 and Scope 2 GHG emissions/revenue from operations adjusted for PPP)	Metric tonnes of CO ₂ equivalent/ crore of US\$	4.41	8,141.12
Total Scope 1 and Scope 2 emission intensity in terms of physical output	Metric tonnes of CO ₂ equivalent/MT product		8.723
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, me of the external agency		No	No

*This FY the numbers are based on standalone and the previous year was in consolidated basis.

8. Does the entity have any project related to reducing Greenhouse Gas emission? If Yes, then provide details.

No

9. Provide details related to waste management by the entity:

Note: Indicate if any independent assessment has been carried out by an external agency? (Y/N) If yes, name the agency.

Category of waste	FY 2025-26	FY 2024-25
Plastic waste (A)	0	0
E-waste (B)	0	0
Bio-medical waste (C)	0	0
Construction and demolition waste (D)	0	0
Battery waste (E)	0	0
Radioactive waste (F)	0	0
Other hazardous waste(G)	0	0
Other non-hazardous waste generated (H)	0	0
Total (A+B + C+ D+E+F+G+H)	0	0
Waste intensity per ₹ of turnover (Total waste generated/revenue from operations)	0	0
Waste intensity per ₹ of turnover adjusted for PPP (Total waste generated/revenue from operations adjusted for PPP)	0	0



Waste intensity in terms of physical output	0	0
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations		
Category of waste	FY 2025-26	FY 2024-25
Recycled (A)	0	0
Re-used(B)	0	0
Other recovery operations(C)	0	0
Total (A+B + C)	0	0
For each category of waste generated, total waste disposed by nature of disposal method		
Category of waste	FY 2025-26	FY 2024-25
Incineration (A)	0	0
Landfilling (B)	0	0
Other disposal operations (C)	0	0
Total (A+B+C)	0	0
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, me of the external agency	No	No

- 10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.**

The Company has adopted a proactive and responsible approach to waste management across its operations. We have implemented internal standards that are aligned with relevant national and international regulations governing hazardous substances, thereby ensuring compliance and environmental stewardship.

As part of our commitment to sustainability and safety, the Company restricts the usage of hazardous chemicals in its manufacturing and operational processes. Where such substances are necessary, their use is closely monitored and managed under strict safety protocols to minimize environmental and health risks.

All categories of waste generated are segregated appropriately and disposed of exclusively through authorized and licensed waste management agencies. These practices ensure that disposal processes adhere to applicable regulatory standards and promote responsible environmental practices. Through these measures, the Company aims to reduce environmental impact, enhance workplace safety, and promote sustainable operations.

- 11. If the entity has operations/offices in/around ecologically sensitive areas (national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals/clearances are required, please specify details, in the following format:**

S. No.	Location of operations/ offices	Location of operations/ offices	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
Not Applicable			

- 12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:**

Name and Brief Details of Project	EIA Notification No.	Date	Conducted by Independent External Agency (Yes/No)	Results Communicated in Public Domain (Yes/No)	Relevant Web Link
Not Applicable					

13. Is the entity compliant with the applicable environmental law/regulations/guidelines in India such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment Protection Act and rules thereunder (Y/N)? If not, provide details of all such non-compliances, in the following format:

Nil

S. No.	Specify the Law / Regulation / Guideline Not Complied With	Details of Non-Compliance	Any Fines / Penalties / Action by Regulatory Agencies / Courts
NA	NA	NA	NA

Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):

For each facility/plant in areas of water stress, provide:

Parameter	FY 2025-26 (Current FY) in kilolitres	FY 2024-25 (Previous FY) in kilolitres
Water Withdrawal by Source (in kiloliters)		
(i) Surface water	0	0
(ii) Groundwater	0	0
(iii) Third party water	0	0
(iv) Seawater / desalinated water	0	0
(v) Others	0	0
Total volume of water withdrawal	0	0
Total volume of water consumption	0	0
Water intensity per rupee of turnover (in kiloliters/Rs crore of revenue)	0	0
Water intensity per rupee of turnover adjusted for PPP	0	0
Water intensity in terms of physical output	0	0
Water intensity (optional – entity may select metric)	0	0

Water discharge by destination and level of treatment:

Parameter	FY 2025-26 (Current FY) in kilolitres	FY 2024-25 (Previous FY) in kilolitres
(i) To Surface water – No treatment	0	0
(i) To Surface water – With treatment (specify level)	0	0
(ii) To Groundwater – No treatment	0	0
(ii) To Groundwater – With treatment (specify level)	0	0
(iii) To Seawater – No treatment	0	0
(iii) To Seawater – With treatment (specify level)	0	0
(iv) Sent to third parties – No treatment	0	0
(iv) Sent to third parties – With treatment (specify level)	0	0
(v) Others – No treatment	0	0
(v) Others – With treatment (specify level)	0	0
Total water discharged (in kilolitres)	0	0
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency	No	No

**2. Please provide details of total Scope 3 emissions & its intensity:**

Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 3 emissions			
Purchased Goods	Metric tonnes of CO2 equivalent	Nil	
Fuel and Energy Related	Metric tonnes of CO2 equivalent	Nil	
Waste generated in operations	Metric tonnes of CO2 equivalent	Nil	
Business Travel	Metric tonnes of CO2 equivalent	Nil	
Employee Commute	Metric tonnes of CO2 equivalent	Nil	
Total Scope 3 emissions (5categories)	Metric tonnes of CO2 equivalent	Nil	123.06
Total Scope 3 emissions per rupee of turnover	Metric tonnes of CO2 equivalent	Nil	111.17
Total Scope 3 emission intensity (in terms of physical output)	Metric tonnes of CO2 equivalent/MT product	Nil	
Total scope 3 emissions per rupee of turnover (Total scope 3 GHG emissions/ turnover in million ₹)	Metric tonnes of CO2 equivalent/ million	Nil	
Total Scope 3 emission intensity in terms of physical output		Nil	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, me of the external agency		No	No

3. With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along with prevention and remediation activities.

NA

4. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions/effluent discharge/waste generated, provide details and outcome, as per the following format:

Sr.No.	Initiative Undertaken	Details of the Initiative (Web-link if any)	Outcome of the Initiative
--------	-----------------------	---	---------------------------

NA

5. Does the entity have a business continuity and disaster management plan? Give details in 100 words / web link.

The Company is currently in the process of developing and formalizing a comprehensive Business Continuity and Disaster Management Plan (BCP/DMP). The proposed framework will focus on identifying potential business disruptions and disaster-related risks, establishing appropriate response and recovery procedures, defining roles and responsibilities, and ensuring continuity of critical business operations.

6. Disclose any significant adverse impact to the environment arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard.

NA

7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

NA

8. How many Green Credits have been generated or procured:

a. By the listed entity - NA

b. By the top ten (in terms of value of purchases and sales, respectively) value chain partners - NA

PRINCIPLE 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

Essential Indicators

1. Affiliations with trade and industry chambers/associations:

a. Number of affiliations with trade and industry chambers/associations:

0

b. List the top 10 trade and industry chambers/associations (determined based on the total members of such body):

Sr. No.	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations (State/National)
	NA	

2. Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by the entity, based on adverse orders from regulatory authorities.

Name of Authority	Brief of the Case	Corrective Action Taken
	Nil	
	NA	
	NA	

Leadership Indicators

1. Details of public policy positions advocated by the entity:

S.No.	Public Policy Advocated	Method Resorted for Advocacy	Information Available in Public Domain? (Yes/No)	Frequency of Review by Board	Web Link, if Available
			Nil		

PRINCIPLE 8: Businesses should promote inclusive growth and equitable development

Essential Indicators

1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.

Name and Brief Details of Project	SIA Notification No.	Date of Notification	Conducted by Independent External Agency (Yes/No)	Results Communicated in Public Domain (Yes/No)	Relevant Web Link
					Not Applicable

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:

S.No.	Name of Project for R&R	State	District	No. of Project Affected Families (PAFs)	% of PAFs Covered by R&R	Amounts Paid to PAFs in FY (INR)
						Not Applicable

**3. Describe the mechanisms to receive and redress grievances of the community.**

Nil

4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:

Input material procured	FY 2025-26	FY 2024-25
Directly sourced from MSMEs/small producers (in %)	35.62%	13.22%
Directly from within India	91.46%	82.64%

5. Job creation in smaller towns – Disclose wages paid to persons employed in the following locations, as % of total wage cost

Location	FY 2025-26	FY 2024-25
Rural	0%	0%
Semi-urban	0%	0%
Urban	0%	21%
Metropolitan	100%	79%

(Place to be categorised as per RBI classification system - rural/semi-urban/urban/ metropolitan)

Leadership Indicators

1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):

Details of Negative Social Impact Identified	Corrective Action Taken
NA	

2. Provide information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:

S.No.	State	Aspirational District	Amount Spent (INR)
NA			

3. Preferential procurement policy:

- (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized/vulnerable groups? (Yes/No)

No

- (b) From which marginalized/vulnerable groups do you procure?

NA

- (c) What percentage of total procurement (by value) does it constitute?

NA

4. Details of benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:

S.No.	Intellectual Property Based on Traditional Knowledge	Owned/Acquired (Yes/No)	Benefit Shared (Yes/No)	Basis of Calculating Benefit Share
	Nil			

5. Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.

Name of authority	Brief of the Case	Corrective action taken
NA		

6. Details of beneficiaries of CSR Projects:

S.No.	CSR Project	No. of persons benefitted from CSR Projects	% of beneficiaries from vulnerable and marginalized group
		Nil	

PRINCIPLE 9: Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.

Fischer Medical Ventures Limited has established a structured and responsive mechanism to receive, address, and resolve consumer complaints and feedback effectively. Consumers can raise concerns through multiple communication channels, including email, telephone, or direct interaction with the Company's sales and service teams.

Complaints are systematically monitored by the relevant operations and quality assurance departments. These teams are responsible for conducting prompt investigations, implementing corrective actions, and ensuring timely resolution.

Furthermore, the Company regularly engages with clients and healthcare stakeholders to gather feedback on service quality. Insights obtained are used to enhance internal processes, strengthen customer relations, and drive continuous improvement. Fischer Medical Ventures Limited remains committed to upholding the highest standards of customer satisfaction and service excellence.

2. Turnover of products and/services as a percentage of turnover from all products/services that carry information about:

	As a percentage to total turnover
Environmental and social parameters relevant to the product	0
Safe and responsible usage	0
Recycling and/or safe disposal	0

3. Number of consumer complaints in respect of the following:

Nature of complaints	FY 2025-26			FY 2024-25		
	Received during the year	Pending resolution at end of year	Remarks	Received during the year	Pending resolution at end of year	Remarks
Data privacy	0	0	NA	0	0	NA
Advertising	0	0	NA	0	0	NA
Cyber-security	0	0	NA	0	0	NA
Delivery of essential services	0	0	NA	0	0	NA
Restrictive Trade Practices	0	0	NA	0	0	NA
Unfair Trade Practices	0	0	NA	0	0	NA
Others	0	0	NA	0	0	NA

4. Details of instances of product recalls on account of safety issues:

Details of instances of product recalls on account of safety issues	No.	Reasons for recall
Voluntary recalls	0	NA
Forced recalls	0	NA

5. Does the entity have a framework/policy on cyber security and risks related to data privacy? (Yes/No). If available, provide a web-link of the policy:

Yes, the weblink is available in the Intranet of the Company accessible to its employees.



- 6. Provide details of any corrective actions taken or underway on issues relating to advertising and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty/action taken by regulatory authorities on safety of products/services.**

Nil

- 7. Provide the following information relating to data breaches:**

- a. Number of instances of data breaches**

0

- b. Percentage of data breaches involving personally identifiable information of customers**

0

- c. Impact, if any, of the data breaches**

Nil

Leadership Indicators

- 1. Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available).**

www.fischermv.com

- 2. Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.**

The Company undertakes comprehensive measures to inform and educate consumers about the safe and responsible usage of its preventive healthcare, medical imaging and diagnostic products. Each product is accompanied by a detailed user manual that outlines safety precautions, operational protocols, and maintenance procedures to ensure proper handling. In addition to written documentation, the Company provides robust post-sales support, including technical training sessions and product demonstrations tailored for healthcare providers and technicians. These initiatives are designed to promote accurate, safe, and efficient product usage in clinical settings.

Furthermore, the Company strictly adheres to all applicable regulatory requirements and labelling standards, thereby ensuring clarity, transparency, and compliance in the communication of product-related information. These efforts collectively reinforce the Company's commitment to patient safety, regulatory integrity, and customer empowerment.

- 3. Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.**

The Company has established robust communication protocols to ensure that consumers are promptly informed of any potential risk of disruption or discontinuation of essential services.

These proactive communication measures are designed to uphold transparency, minimize service interruptions, and ensure continuity of care, particularly for healthcare providers and critical service users. By facilitating timely awareness and access to support or alternative solutions, the Company reinforces its commitment to service reliability and stakeholder trust.

- 4. Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable). If yes, provide details. Did your entity carry out any survey with regard to consumer satisfaction relating to the major products/services of the entity? (Yes/No)**

Yes, The Company ensures full compliance with all applicable regulatory requirements relating to product information under the Medical Device Rules, 2017, administered by CDSCO, as well as other relevant standards. In addition to statutory disclosures, the Company voluntarily provides supplementary information such as handling instructions, installation and maintenance guidelines, safety precautions, and dedicated customer support contact details to promote responsible usage and enhance user experience.

To evaluate consumer satisfaction, the Company conducts periodic feedback interactions with hospitals, diagnostic centres, and channel partners across its key markets. Insights from these engagements are systematically analyzed and integrated into product design, service delivery, and customer support processes, reinforcing the Company's commitment to quality, safety, and customer-centricity.